Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 1997

View Archived Issues

UCSF receives NIH funding for research into anticancer protease inhibitors

Genentech granted U.S. patents for factor VIII

Selective 5-HT1Dalpha receptor agonists from MS&D

Astra prepares NOS inhibitors

Antiviral dihydropyrans from Biota

Synthelabo prepares serotonergic agents

Arzneimittelwerk describes novel antiepileptic agents

Synthelabo reports agents for urinary incontinence

First launch for new indication of cabergoline

Aldara approved in U.S.

MDR-reversing agents described by Nikken Chemicals

Fujsawa selects adenosine A1 receptor antagonist for development

Fujisawa describes new oral cephem antibiotic

Eisai prepares potent antitumor agents

TX-1877: new hypoxic cell radiation enhancer

Lilly granted rights to gene/protein involved in islet neogenesis

RPR cleared to market Taxotere in Malaysia and Hungary

Encouraging phase III results reported for lamivudine as hepatitis B treatment

Wyeth-Ayerst and Elan develop new formulation of Lodine

Milestone reached in Genome Therapeutics/Astra H. pylori collaboration

Progress in Cubist/Bristol-Myers Squibb antiinfective collaboration

Treatment for rhinitis undergoes further development in Australia

Hybridon selects HPV drug candidate

Encouraging results from preclinical trial of Atlantic's RSV therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....